Share-based Payment Arrangement, Expense of Armata Pharmaceuticals, Inc. from 31 Mar 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Armata Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2013 to 30 Sep 2025.
  • Armata Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $622,000, a 7.2% decline year-over-year.
  • Armata Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,332,000, a 15% decline year-over-year.
  • Armata Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,893,000, a 208% increase from 2023.
  • Armata Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $938,000, a 70% decline from 2022.
  • Armata Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,105,000, a 7.7% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Armata Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,332,000 $622,000 -$48,000 -7.2% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $2,380,000 $575,000 -$760,000 -57% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $3,140,000 $781,000 +$247,000 +46% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $2,893,000 $354,000 +$161,000 +83% 01 Oct 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
Q3 2024 $2,732,000 $670,000 +$1,043,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $1,689,000 $1,335,000 +$1,074,000 +411% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $615,000 $534,000 -$323,000 -38% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $938,000 $193,000 -$624,000 -76% 01 Oct 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
Q3 2023 $1,562,000 $373,000 -$1,219,000 -144% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $2,781,000 $261,000 -$688,000 -72% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $3,469,000 $857,000 +$364,000 +74% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $3,105,000 $817,000 +$153,000 +23% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $2,952,000 $846,000 +$377,000 +80% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $2,575,000 $949,000 +$42,000 +4.6% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $2,533,000 $493,000 -$349,000 -41% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,882,000 $664,000 -$198,000 -23% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $3,080,000 $469,000 -$194,000 -29% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $3,274,000 $907,000 +$1,000 +0.11% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,273,000 $842,000 -$202,000 -19% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $3,475,000 $862,000 -$87,000 -9.2% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
Q3 2020 $3,562,000 $663,000 -$1,835,000 -73% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $5,397,000 $906,000 +$182,000 +25% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $5,215,000 $1,044,000 +$945,000 +955% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $4,270,000 $949,000 +$1,046,000 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $3,224,000 $2,498,000 +$2,490,000 +31125% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $734,000 $724,000 +$711,000 +5469% 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2020 Q2
Q1 2019 $23,000 $99,000 -$23,000 -19% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2019 2019 Q1
Q4 2018 $46,000 $97,000 -$229,000 -173% 01 Oct 2018 31 Dec 2018 10-K 19 Mar 2020 2019 FY
Q3 2018 $275,000 $8,000 -$90,000 -92% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $365,000 $13,000 -$286,000 -96% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $651,000 $122,000 -$49,000 -29% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q4 2017 $700,000 $132,000 -$165,000 -56% 01 Oct 2017 31 Dec 2017 10-K 25 Mar 2019 2018 FY
Q3 2017 $865,000 $98,000 -$236,000 -71% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $1,101,000 $299,000 -$249,000 -45% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $1,350,000 $171,000 -$645,000 -79% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 $1,995,000 $297,000 +$67,000 +29% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2018 2017 FY
Q3 2016 $1,928,000 $334,000 +$185,000 +124% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 $1,743,000 $548,000 +$496,000 +954% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $1,247,000 $816,000 +$764,000 +1469% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $483,000 $230,000 +$171,000 +290% 01 Oct 2015 31 Dec 2015 10-K 27 Mar 2017 2016 FY
Q3 2015 $312,000 $149,000 -$1,259,000 -89% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $1,571,000 $52,000 -$183,000 -78% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $1,754,000 $52,000 -$182,000 -78% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 $1,936,000 $59,000 -$173,000 -75% 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
Q3 2014 $2,109,000 $1,408,000 +$1,160,000 +468% 01 Jul 2014 30 Sep 2014 10-Q 16 Nov 2015 2015 Q3
Q2 2014 $949,000 $235,000 -$568,000 -71% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $1,517,000 $234,000 +$80,000 +52% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q1
Q4 2013 $1,437,000 $232,000 01 Oct 2013 31 Dec 2013 10-K 15 Apr 2015 2014 FY
Q3 2013 $248,000 01 Jul 2013 30 Sep 2013 10-Q/A 15 Apr 2015 2014 Q3
Q2 2013 $803,000 01 Apr 2013 30 Jun 2013 10-Q/A 15 Apr 2015 2014 Q2
Q1 2013 $154,000 01 Jan 2013 31 Mar 2013 10-Q/A 15 Apr 2015 2014 Q1

Armata Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,893,000 +$1,955,000 +208% 01 Jan 2024 31 Dec 2024 10-K 21 Mar 2025 2024 FY
2023 $938,000 -$2,167,000 -70% 01 Jan 2023 31 Dec 2023 10-K 21 Mar 2025 2024 FY
2022 $3,105,000 +$223,000 +7.7% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $2,882,000 -$593,000 -17% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $3,475,000 -$795,000 -19% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
2019 $4,270,000 +$4,224,000 +9183% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $46,000 -$654,000 -93% 01 Jan 2018 31 Dec 2018 10-K 19 Mar 2020 2019 FY
2017 $700,000 -$1,295,000 -65% 01 Jan 2017 31 Dec 2017 10-K 25 Mar 2019 2018 FY
2016 $1,995,000 +$1,512,000 +313% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2018 2017 FY
2015 $483,000 -$1,453,000 -75% 01 Jan 2015 31 Dec 2015 10-K 27 Mar 2017 2016 FY
2014 $1,936,000 +$499,000 +35% 01 Jan 2014 31 Dec 2014 10-K 30 Mar 2016 2015 FY
2013 $1,437,000 01 Jan 2013 31 Dec 2013 10-K 15 Apr 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.